DINA 002
Alternative Names: DINA-002Latest Information Update: 03 Jan 2023
Price :
$50 *
At a glance
- Originator DiNAQOR AG
- Class Cardiovascular therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cardiomyopathies
Most Recent Events
- 02 Jan 2023 Preclinical trials in Cardiomyopathies in Switzerland (Intracardiac) as of January 2023 (DiNAQOR pipeline, January 2023)
- 31 Jan 2020 DiNAQOR has patents pending for DINA 002 (DiNAQOR pipeline, January 2020)
- 31 Jan 2020 Early research in Cardiomyopathies in Switzerland (Intracardiac) (DiNAQOR pipeline, January 2020)